Other equities analysts have also issued reports about the stock. Deutsche Bank reiterated a buy rating and set a GBX 775 ($10.36) target price on shares of BTG in a research report on Tuesday, November 7th. Stifel Nicolaus reiterated a buy rating and set a GBX 800 ($10.70) target price on shares of BTG in a research report on Wednesday, August 30th. Peel Hunt restated a hold rating and issued a GBX 680 ($9.09) price objective on shares of BTG in a report on Wednesday, September 20th. Finally, JPMorgan Chase & Co. restated a neutral rating on shares of BTG in a report on Wednesday, November 15th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of Buy and an average price target of GBX 771.63 ($10.32).
BTG (LON BTG) traded down GBX 9.79 ($0.13) during midday trading on Friday, reaching GBX 752.71 ($10.06). 475,106 shares of the company were exchanged, compared to its average volume of 500,794. The company has a market capitalization of $2,910.00 and a PE ratio of 3,961.63. BTG has a twelve month low of GBX 528.36 ($7.06) and a twelve month high of GBX 784 ($10.48).
BTG (LON:BTG) last issued its quarterly earnings data on Tuesday, November 14th. The company reported GBX 21 ($0.28) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of GBX 21 ($0.28). The firm had revenue of £341.30 million for the quarter. BTG had a net margin of 15.50% and a return on equity of 10.80%.
ILLEGAL ACTIVITY WARNING: “BTG (BTG) Rating Reiterated by Numis Securities” was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.truebluetribune.com/2018/01/03/btgs-btg-buy-rating-reiterated-at-numis-securities.html.
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.